Survodutide vs tirzepatide: how the two actually compare

The core difference: glucagon vs GIP

Both survodutide and tirzepatide build on GLP-1. That is where the similarity ends. Tirzepatide's second receptor is GIP, the glucose-dependent insulinotropic polypeptide. GIP amplifies insulin release and, at the doses tirzepatide delivers, appears to reduce the nausea that GLP-1 agonism alone causes. It makes the drug more tolerable and probably more effective than either receptor alone.

Survodutide's second receptor is glucagon. Glucagon receptors sit mainly in the liver. Activating them tells the liver to burn fatty acids directly, raising baseline energy expenditure. The liver starts working through stored fat regardless of how much you are eating or moving. That is a different mechanism than GIP. GIP amplifies insulin signaling. Glucagon targets hepatic fat metabolism directly.

Eli Lilly put both receptors into retatrutide alongside GLP-1. But tirzepatide and survodutide are the cleaner comparison: same class, same general concept, genuinely different second bets.

Weight loss: where tirzepatide leads

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight. At 72 weeks on the 15mg dose, mean weight loss was 20.9%. That is the published pivotal trial result. At the 10mg dose, it was 19.5%. These are the numbers the FDA reviewed for approval.

SYNCHRONIZE-1 enrolled 725 adults over 76 weeks. At the top dose of 6mg, survodutide produced 16.6% mean weight loss. That is meaningful. But it trails tirzepatide by roughly 4 percentage points.

At 250 lbs starting weight, the difference between 16.6% and 20.9% is about 11 lbs. At 300 lbs, it is about 13 lbs. That gap is real. It matters. It is also not the whole comparison.

Where survodutide wins: liver fat and visceral fat

Most obesity trials measure total body weight. A smaller number measure body composition with DXA. Almost none do MRI imaging of specific fat depots. SYNCHRONIZE-1 did, and the numbers are striking.

Visceral fat fell 34%. Liver fat fell 63.1%. These are direct imaging measurements of the fat that matters most metabolically, not extrapolations from scale weight.

Visceral fat sits inside the abdominal cavity, wrapped around the organs. It is the fat that drives insulin resistance, systemic inflammation, and cardiovascular risk in a way that subcutaneous fat does not. You can drop 30 lbs from your hips and thighs while visceral fat barely moves. Most trials do not tell you which fat you lost. This one did.

The 63% liver fat reduction connects directly to why the FDA granted survodutide Breakthrough Therapy designation for MASH (metabolic-associated steatohepatitis) in September 2024. Fatty liver disease affects roughly 40% of the global population. The GLP-1 MASH approval for semaglutide established that weight loss drugs can address liver disease directly. Survodutide is making the same argument with better liver-specific data.

Tirzepatide's Phase 2 MASH trial showed 44% of participants achieving MASH resolution versus 10% on placebo. A meaningful result. But the trial designs differ enough that direct percentage comparisons are misleading. What you can say: both drugs move liver disease, and survodutide's glucagon mechanism gives it a more direct shot at hepatic fat metabolism by design.

Lean mass: a difference worth watching

Every weight loss drug loses some muscle alongside fat. The ratio is what matters. GLP-1 class drugs generally show lean mass accounting for 25 to 40% of total tissue weight lost. That has driven real concern about skeletal muscle loss in people on these drugs long-term.

In SYNCHRONIZE-1, lean mass was 10.8% of total tissue mass change at the highest dose. That is meaningfully lower than what tirzepatide and semaglutide have shown in comparable analyses. Whether this comes from the glucagon receptor mechanism specifically, or from the particular trial population, or from some interaction in the titration protocol, is not yet established. The SYNCHRONIZE-1 researchers did not overclaim it. But the number is there in the published data.

If the muscle preservation signal holds in future analyses, it would be a genuine differentiator. For anyone concerned about muscle loss on a GLP-1, this is a data point worth tracking as more survodutide trials report.

Side effects and tolerability

Both drugs cause GI side effects during dose escalation. Nausea, vomiting, diarrhea, constipation. This is the GLP-1 mechanism at work and applies to the whole class. The question is degree.

Survodutide adds glucagon-related effects: elevated heart rate at higher doses, and some increase in hepatic glucose output. In Phase 2 obesity studies, roughly 8% of participants stopped taking survodutide at the highest doses due to GI adverse events. Boehringer uses a 4-step titration protocol specifically to manage this, and the Phase 3 tolerability picture is somewhat better. The cardiovascular outcomes trial (SYNCHRONIZE-CVOT) is the right place to watch the heart rate question. Its results are expected in 2026.

Tirzepatide's SURMOUNT trials showed discontinuation rates in the 5 to 7% range. The GIP component is thought to dampen nausea during titration, which contributes to better tolerability than semaglutide at equivalent doses. On tolerability, tirzepatide currently has the better track record across a larger set of patients.

Current indications: tirzepatide has a wider label

Tirzepatide carries FDA approval for three indications. Obesity and overweight with a comorbidity (Zepbound). Type 2 diabetes (Mounjaro). And sleep apnea, following the SURMOUNT-OSA trial showing up to 63% lower apnea severity. That breadth matters for insurance coverage and for patients with multiple metabolic conditions.

Survodutide has no FDA approvals. The Breakthrough Therapy designation for MASH speeds the review process once a submission is filed, but no submission has been filed. The obesity indication requires the SYNCHRONIZE-CVOT cardiovascular results before Boehringer will file. The MASH trial (SYNCHRONIZE-MASLD) is still reading out.

Survodutide vs tirzepatide: the access gap

This is the deciding factor for most people reading this comparison. Tirzepatide exists. It is accessible through telehealth providers today. Survodutide is at minimum 18 months away under the most optimistic timeline, and probably longer.

If your primary concern is liver disease or fatty liver on top of obesity, survodutide has a more targeted mechanism. But it is not available, and tirzepatide has its own meaningful liver data. If your primary concern is maximum weight loss right now, tirzepatide wins on both the efficacy numbers and the fact that it actually exists as a product. Check the best GLP-1 programs for what is accessible today.

The drugs to genuinely watch are survodutide (for the CVOT results and MASH data), and retatrutide (which adds GIP to the glucagon mechanism and has posted 28.3% weight loss in TRIUMPH-1). Neither is available. Both will reshape the landscape when they arrive.

For now, tirzepatide is what exists. And the full SYNCHRONIZE-1 data gives you a real picture of what survodutide might deliver when it eventually lands.